CN106822889A - A kind of immune programme for children for improving pig vaccine synergetic immunity qualification rate - Google Patents
A kind of immune programme for children for improving pig vaccine synergetic immunity qualification rate Download PDFInfo
- Publication number
- CN106822889A CN106822889A CN201710159214.7A CN201710159214A CN106822889A CN 106822889 A CN106822889 A CN 106822889A CN 201710159214 A CN201710159214 A CN 201710159214A CN 106822889 A CN106822889 A CN 106822889A
- Authority
- CN
- China
- Prior art keywords
- vaccine
- pig
- children
- immune
- prescribed dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/10011—Arteriviridae
- C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
The invention discloses it is a kind of improve pig vaccine synergetic immunity qualification rate immune programme for children, by swine rearing to 50 ages in days, and to basic antibody titer determine after, carry out as follows：1st day neck bilateral intramuscular injection prescribed dose live vaccines of hog cholera, the O-shaped inactivated foot-and-mouth disease vaccine of pig, the 21st day porcine reproductive and respiratory syndrome inactivated vaccine of neck branch intramuscular injection prescribed dose.Immune programme for children of the present invention changes the O-shaped inactivated foot-and-mouth disease vaccine of existing live vaccines of hog cholera, pig and porcine reproductive and respiratory syndrome inactivated vaccine is spaced 7~14 natural gift and is immunized for 3 times as 2 times immune, simplify program, Immune efficiency, immune antiboidy potency and qualification rate are improve, live vaccines of hog cholera immuno-competent rate is averagely improved 21.86%.
Description
Technical field
Inactivated the invention belongs to breeding technique field, more particularly to a kind of O-shaped aftosa of live vaccines of hog cholera, pig that improves
Vaccine and porcine reproductive and respiratory syndrome inactivated vaccine are while the immune programme for children of immuno-competent rate, specifically a kind of to improve
The immune programme for children of pig vaccine synergetic immunity qualification rate.
Background technology
China is traditional livestock culturing big country, and various infectious diseases govern the development of China's pig industry always, to people
People's production and living also result in extreme influence.Countries in the world take the generation that various methods prevent pig infectious disease, wherein most
Effectively to carry out vaccine inoculation to pig.But because China is also weaker to the prevention and control basis of schweineseuche disease, epidemic prevention, inspection
Epidemic disease, monitoring means are not well established and perfect, and quarantine team of basic unit 5 is unstable, lack the means and experience of extensive control schweineseuche disease,
And various regions pig scale is different with epidemic prevention condition, and differ greatly, cause pig vaccine immuno-competent rate not high, or even immune journey
Sequence fails, and especially various vaccine synergetic immunities are rarely reported.Therefore, the immune programme for children of the various vaccine synergetic immunities of research and probe
It is very necessary.
At present, the report about immune programme for children is more, but is mostly independent relative immunity, such as《4 kinds of swine fevers of large-scale pig farm
The immune effect of immune programme for children compares》(Lin Yi, Feng Jinchuan, Zhang Daoyong etc.,<Chinese animal doctor's science and technology>,2000,30(4):21-22)
" hog cholera immune antibody mediated immunity program and testing result " is disclosed, it formulates immune programme for children according to pig age, using triple vaccine (pig
Pest bull testis cell weak-toxic vaccine-and swine fever-swine plague-brickpox) immunoassays are carried out, obtaining optimum immuning program is：28
Age in days head exempts from, and 70 ages in days two exempt from 2 parts of hog cholera vaccines, significant to China's swine fever prevention and control, but because pig is in feeding process
In, its threat for often being faced with various epidemic diseases, only carrying out prevention and control by independent vaccine obviously can not reach requirement.And use various
When vaccine carries out simultaneously immune, there is that immuno-competent rate is poor again, or even the immune problem for failing.
The content of the invention
It is an object of the invention to：A kind of raising live vaccines of hog cholera, the O-shaped inactivated foot-and-mouth disease vaccine of pig and pig breeding are provided
With respiration syndrome inactivated vaccine while the immune programme for children of immuno-competent rate, agent is specified by using neck bilateral intramuscular injection in the 1st day
Amount live vaccines of hog cholera, the O-shaped inactivated foot-and-mouth disease vaccine of pig, the 21st day neck branch intramuscular injection prescribed dose porcine reproductive and respiratory syndrome
The immune programme for children of inactivated vaccine, makes three kinds of vaccine immunity qualification rates require immuno-competent rate standard up to the Ministry of Agriculture.
To achieve these goals, the present invention is adopted the following technical scheme that：
A kind of immune programme for children for improving pig vaccine synergetic immunity qualification rate, it is characterised in that：By swine rearing to 50 ages in days, and
After being determined to basic antibody titer, carry out as follows：Neck bilateral intramuscular injection prescribed dose live vaccines of hog cholera, pig are O-shaped within 1st day
Inactivated foot-and-mouth disease vaccine, the 21st day porcine reproductive and respiratory syndrome inactivated vaccine of neck branch intramuscular injection prescribed dose.
Further, the prescribed dose of described live vaccines of hog cholera is 1ml, the rule of the O-shaped inactivated foot-and-mouth disease vaccine of described pig
Dosage is determined for 2ml.
Further, the prescribed dose of described porcine reproductive and respiratory syndrome inactivated vaccine is 2ml.
Compared with prior art, the beneficial effects of the present invention are：
1) immune programme for children of the present invention changes the O-shaped inactivated foot-and-mouth disease vaccine of existing live vaccines of hog cholera, pig and pig breeding and breathes comprehensive
Simulator sickness inactivated vaccine is spaced 7~14 natural gift and is immunized for 3 times as 2 times immune, simplifies program, improves Immune efficiency, immune antiboidy
Potency and qualification rate, make live vaccines of hog cholera immuno-competent rate averagely improve 21.86%.
2) by immune programme for children of the present invention, the suggestion of production swine fever and the O-shaped aftosa duplex vaccine of pig is proposed first, be
China's pig control and prevention of disease serves guiding function.
3) vaccine immunity qualification rate is effectively increased using immune programme for children of the present invention, it is ensured that epidemic prevention quality, is implementing to answer
With in 4 years, there is no the O-shaped aftosa of swine fever, pig, porcine reproductive and respiratory syndrome epidemic situation in experiment pig farm, achieve good
Society, economy and ecological benefits.
4) immune programme for children of the present invention reduces the workload of epidemic prevention worker, saves substantial amounts of human and material resources, solves conscientiously
Livestock technology department vaccine program disunity, effectively immune antiboidy level is low, immuno-competent rate is not up to standard practical problem, drop
Low scale pig morbidity and mortality, improve pig economic benefit, reduce sick dead pig body and disorderly throw and throw out without care and epidemic disease is dirty
Pollution of the dye thing to water source environment, has purified air and water source, protects ecological environment, reduces livestock products medicament residue, is
Development green non-pollution livestock products are provided with the benign ecological circulation developing goal for realizing modern agriculture aquaculture synergy and ensured,
To ensure the criterion of acceptability that three kinds of vaccine immunities specify up to the Ministry of Agriculture, it is ensured that without animal epidemic generation of setting up defences, it is ensured that Ren Minqun
Many healthy and social stabilitys, it is ensured that pig industry is lasting, quick, stable, developing in a healthy way provides powerful guarantee.
Specific embodiment
Technical scheme is described further with reference to specific embodiment, in order to same domain technical staff
Understanding.
Embodiment 1
1.1 basic antibody titers are determined
To raising to the test pig of 50 ages in days, serum is taken a blood sample and separated in 10% ratio, determine basic antibody titer, its
In, swine fever (CSF) and the O-shaped aftosa of pig (FMD) use IHA methods, and porcine reproductive and respiratory syndrome (PRRS) uses ELISA method,
Basic antibody titer record sees attached list 1.
Subordinate list 1- bases antibody titer detection statistics table
1.2 immunization methods
1.2.1 test pig data
Knowable to subordinate list 1, CSF and FMD basis antibody titers ㏒ of equal ＜ 1 after measured2, PRRS is detected and is feminine gender, and choosing is tried
Pig 84 is tested, 6 groups are randomly divided into, every group 14,1-3 groups are test group, and 4-6 groups are control group.
1.2.2 immune programme for children
1) live vaccines of hog cholera (cell source) and the O-shaped aftosa of pig of 1 group of the 1st day neck Bilateral injections prescribed dose of experiment go out
Live vaccine, the 7th day porcine reproductive and respiratory syndrome inactivated vaccine of neck branch intramuscular injection prescribed dose；
2) 2 groups of live vaccines of hog cholera (cell source) of the 1st day neck bilateral intramuscular injection prescribed dose, O-shaped aftosas of pig of experiment are gone out
Live vaccine, neck branch injects the porcine reproductive and respiratory syndrome inactivated vaccine of prescribed dose within the 14th day；
3) the O-shaped mouth hoof inactivation of 3 groups of live vaccines of hog cholera (cell source) of the 1st day neck Bilateral injections prescribed dose, pig is tested
Vaccine, neck branch injects the porcine reproductive and respiratory syndrome inactivated vaccine of prescribed dose within the 21st day,
4) 4-6 groups the 1st day respectively the live vaccines of hog cholera (cell source) of injection prescribed dose, the O-shaped inactivated foot-and-mouth disease vaccine of pig,
Porcine reproductive and respiratory syndrome inactivated vaccine, clinical observation 3~5 days after injection.
1.2.3 immune antiboidy titration
To test pig when last time vaccinates immune 28 days, blood sampling determines immune antiboidy potency, measure side
Method sees attached list 2 with basis antibody titer, measurement result.
Subordinate list 2- immune antiboidies potency is recorded
1.3 result of the tests
Knowable to subordinate list 2：
1) 1 group of live vaccines of hog cholera (cell source), the O-shaped inactivated foot-and-mouth disease vaccine of pig, porcine reproductive and respiratory syndrome of experiment go out
Live vaccine immuno-competent rate is respectively 100%, 14.3%, 42.9%, and the O-shaped inactivated foot-and-mouth disease vaccine of pig, pig breeding and breathing are comprehensive
Simulator sickness inactivated vaccine immuno-competent rate does not specify immuno-competent rate standard up to the Ministry of Agriculture；
2) 2 groups of live vaccines of hog cholera (cell source), the O-shaped inactivated foot-and-mouth disease vaccine of pig, porcine reproductive and respiratory syndromes of experiment go out
Live vaccine immuno-competent rate is respectively 100%, 57.1%, 57.1%, and the O-shaped inactivated foot-and-mouth disease vaccine of pig, pig breeding and breathing are comprehensive
Simulator sickness inactivated vaccine immuno-competent rate does not specify immuno-competent rate standard up to the Ministry of Agriculture；
3) 3 groups of live vaccines of hog cholera (cell source), the O-shaped inactivated foot-and-mouth disease vaccine of pig, porcine reproductive and respiratory syndromes of experiment go out
Live vaccine immuno-competent rate is respectively 100%, 85.7%, 85.7%, and three kinds of vaccine immunity qualification rates are exempted from up to Ministry of Agriculture's regulation
Epidemic disease yield criterion；
4) live vaccines of hog cholera (cell source), the O-shaped inactivated foot-and-mouth disease vaccine of pig, porcine reproductive and respiratory syndrome inactivated vaccine pair
92.9%, 78.6%, 85.7% is respectively according to a group immuno-competent rate, immuno-competent rate specifies immuno-competent rate mark up to the Ministry of Agriculture
It is accurate.
Therefore, proved by above-mentioned experiment, immune programme for children of the invention achieves significant technique effect, be swine fever work epidemic disease
Seedling (cell source), the O-shaped inactivated foot-and-mouth disease vaccine of pig, porcine reproductive and respiratory syndrome inactivated vaccine synergetic immunity provide direction,
Also it is the suggestion of production swine fever and the O-shaped aftosa duplex vaccine of pig, is that China's pig control and prevention of disease serves guiding function.
Claims (3)
1. it is a kind of improve pig vaccine synergetic immunity qualification rate immune programme for children, it is characterised in that：It is by swine rearing to 50 ages in days and right
After basic antibody titer is determined, carry out as follows：1st day neck bilateral intramuscular injection prescribed dose live vaccines of hog cholera, the O-shaped mouth of pig
Fever aphthous inactivated vaccine, the 21st day porcine reproductive and respiratory syndrome inactivated vaccine of neck branch intramuscular injection prescribed dose.
2. a kind of immune programme for children for improving pig vaccine synergetic immunity qualification rate as claimed in claim 1, it is characterised in that：It is described
The prescribed dose of live vaccines of hog cholera be 1ml, the prescribed dose of the O-shaped inactivated foot-and-mouth disease vaccine of described pig is 2ml.
3. a kind of immune programme for children for improving pig vaccine synergetic immunity qualification rate as claimed in claim 1, it is characterised in that：It is described
Porcine reproductive and respiratory syndrome inactivated vaccine prescribed dose be 2ml.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710159214.7A CN106822889A (en) | 2017-03-17 | 2017-03-17 | A kind of immune programme for children for improving pig vaccine synergetic immunity qualification rate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710159214.7A CN106822889A (en) | 2017-03-17 | 2017-03-17 | A kind of immune programme for children for improving pig vaccine synergetic immunity qualification rate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106822889A true CN106822889A (en) | 2017-06-13 |
Family
ID=59143768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710159214.7A Pending CN106822889A (en) | 2017-03-17 | 2017-03-17 | A kind of immune programme for children for improving pig vaccine synergetic immunity qualification rate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106822889A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1966079A (en) * | 2006-11-15 | 2007-05-23 | 张中洋 | Immunoglobulin for resisting O and Asia I type foot and mouth disease used for cow and pig |
| CN102973932A (en) * | 2011-09-07 | 2013-03-20 | 普莱柯生物工程股份有限公司 | Trivalent inactivated vaccine of porcine reproductive and respiratory syndrome virus, porcine circovirus type 2, and porcine pseudorabies virus and preparation method thereof |
-
2017
- 2017-03-17 CN CN201710159214.7A patent/CN106822889A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1966079A (en) * | 2006-11-15 | 2007-05-23 | 张中洋 | Immunoglobulin for resisting O and Asia I type foot and mouth disease used for cow and pig |
| CN102973932A (en) * | 2011-09-07 | 2013-03-20 | 普莱柯生物工程股份有限公司 | Trivalent inactivated vaccine of porcine reproductive and respiratory syndrome virus, porcine circovirus type 2, and porcine pseudorabies virus and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Van Oirschot et al. | Marker vaccines, virus protein-specific antibody assays and the control of Aujeszky's disease | |
| CN103627678B (en) | A kind of porcine pseudorabies virus variant PRV-ZJ01 and application | |
| CN105688202B (en) | A kind of Vaccinum Encephalitis B composition and preparation method thereof | |
| CN110387354A (en) | Pseudorabies virus Attenuation strain and its application | |
| CN101915837B (en) | Method for testing efficacy of hog cholera lapinized virus live vaccine | |
| CN104043117B (en) | A kind of vaccine combination and its preparation method and application | |
| Gao et al. | The new porcine epidemic diarrhea virus outbreak may mean that existing commercial vaccines are not enough to fully protect against the epidemic strains | |
| CN105548536A (en) | Method for preparing positive serum of antibody against porcine Japanese encephalitis virus | |
| CN104288760A (en) | Vaccine composition, and preparation method and application thereof | |
| CN107589256A (en) | The method of inspection of the type of Haemophilus parasuis 4,5 type bivalent inactivated vaccine effect | |
| CN102716479A (en) | Pig breeding and respiratory syndrome NVDC-JXA1 strain-porcine parvovirus disease duplex inactivated vaccine and preparation method and application thereof | |
| CN102727881A (en) | Highly pathogenic porcine reproductive and respiratory syndrome JXAl-R strain- porcine parvovirus disease bigeminal live vaccine and preparation method and application thereof | |
| CN106474467A (en) | Pseudoabies inactivated vaccine and preparation method thereof | |
| CN106822889A (en) | A kind of immune programme for children for improving pig vaccine synergetic immunity qualification rate | |
| CN106822888B (en) | Peste des petits ruminants and goat pox combined live vaccine and production method thereof | |
| CN103123350B (en) | Preparation method for positive serum by porcine reproductive and respiratory syndrome virus | |
| CN105582535A (en) | Preparation method of CSF (Classical Swine Fever) and PR (Pseudorabies) bivalent live vaccine and product of CSF and PR bivalent live vaccine | |
| CN102727882B (en) | Combined live vaccine against porcine reproductive and respiratory syndrome, swine fever and pseudorabies, and preparation method thereof | |
| CN101380470B (en) | Pig parvovirus live vaccine | |
| Jiang et al. | Immune efficacy of a candidate porcine reproductive and respiratory syndrome vaccine rHN-NP49 administered by a Needle-free intradermal delivery system in comparison with intramuscular injection | |
| CN107338227A (en) | Bovine parainfluenza virus PBIV3 B strains and its application | |
| CN104288762A (en) | Vaccine composition, and preparation method and application thereof | |
| CN111551747A (en) | Method for testing efficacy of porcine epikavirus inactivated vaccine by using rabbit based on antibody detection | |
| Balyshev et al. | Seroimmunological affiliation of African swine fever virus isolated in the Russian Federation | |
| US3122477A (en) | Hog cholera vaccine and method of making the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |